Percutaneous Coronary Intervention
Within two decades, MicroPort® has transformed itself from a market follower, into a global leader in the field of Percutaneous Coronary Intervention (PCI). Its proprietary Firehawk® targeted eluting stent system, with proven clinical evidence in terms of safety and efficacy, has become a leading stent, setting industry standards for a new generation of global cardiac stents.
Rapamycin Target Eluting Coronary Stent System
Firehawk® as the first and only Target Eluting Stent (TES), features over 600 groves on the stent strut surface, and a target release technology that allows for 1/3 of the dosage versus conventional stents.
The result is a unique solution that combines the strength of both drug eluting stents and bare metal stents.
With the continuous increase in the body of clinical evidence to demonstrate its 'golden standard' in safety and efficacy, Firehawk® is establishing its status as an elite workhorse drug-eluting stent for clinics across the globe.
Firehawk LibertyTM is the next generation TES combining the excellence, deliverability, and proven safety and efficacy of Firehawk®.
Firebird2 is the first Chinese drug eluting stent with Cobalt-Chromium platform. It has been widely used and recognized both in China and internationally to fulfill the need of treating patients with Coronary Artery Disease.